Fig. 1

PD-L1-AAV particles targeting PD-L1 exon 3 were designed and engineered as described in previous experiments. Thereafter, we established an AAV-CRISPR/Cas9 system to deliver genome editing of PD-L1 on tumors in vivo. PD-L1-specific gRNA/Cas9 systems were constructed using gRNA targeted to Cd274 (Pdl1) exon 3, which were delivered using AAV vectors, and their ability to suppress the PD-L1 gene in ID8 cells was assessed. These control AAV and PD-L1-AAV particles were used in subsequent experiments. (Modified from references number 41)